Literature DB >> 30573343

Controversies in drug allergy: In vitro testing.

Cristobalina Mayorga1, Didier G Ebo2, David M Lang3, Werner J Pichler4, Vito Sabato2, Miguel A Park5, Joanna Makowska6, Marina Atanaskovic-Markovic7, Patrizia Bonadonna8, Edgardo Jares9.   

Abstract

Despite their low frequency, drug hypersensitivity reactions (DHRs) can be serious and result in lifelong sequelae. The diagnosis is critical to avert future reactions and should identify the culprit drug or drugs and safe alternatives. However, making the diagnosis can be complex and challenging. Reliable in vitro tests can offer the potential to improve a diagnosis of DHR and influence medical decision making. Importantly, in vitro testing is frequently not performed as a test in isolation but rather as a component of a diagnostic algorithm along with additional tests. There are several in vitro approaches for the different endotypes of DHRs. However, only few are available for routine diagnosis, and many are restricted to research laboratories. In vitro tests exhibit varying sensitivity and specificity depending on the drug involved and the clinical phenotype. In vitro tests can complement skin tests, especially in patients with negative or equivocal skin test responses inconsistent with the clinical presentation and in severe reactions in which drug provocation tests are contraindicated. The main unmet need for many in vitro tests for the diagnosis of DHRs is validation in larger studies with standardized controls that could harmonize diagnostic management between the United States, European Union, and other regions of the world.
Copyright © 2018 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Drug hypersensitivity; IgE; T-cells; anaphylaxis; cytokine; diagnostic; in vitro tests; p-i concept; proliferation; severe cutaneous reactions

Mesh:

Year:  2018        PMID: 30573343     DOI: 10.1016/j.jaci.2018.09.022

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  14 in total

Review 1.  The challenge of de-labeling penicillin allergy.

Authors:  Cosby A Stone; Jason Trubiano; David T Coleman; Christine R F Rukasin; Elizabeth J Phillips
Journal:  Allergy       Date:  2019-05-26       Impact factor: 13.146

Review 2.  Advances and highlights in biomarkers of allergic diseases.

Authors:  Ismail Ogulur; Yagiz Pat; Ozge Ardicli; Elena Barletta; Lacin Cevhertas; Ruben Fernandez-Santamaria; Mengting Huang; Manal Bel Imam; Jana Koch; Siyuan Ma; Debbie J Maurer; Yasutaka Mitamura; Yaqi Peng; Urszula Radzikowska; Arturo O Rinaldi; Juan Rodriguez-Coira; Pattraporn Satitsuksanoa; Stephan R Schneider; Alexandra Wallimann; Damir Zhakparov; Reihane Ziadlou; Marie-Charlotte Brüggen; Willem van de Veen; Milena Sokolowska; Katja Baerenfaller; Luo Zhang; Mubeccel Akdis; Cezmi A Akdis
Journal:  Allergy       Date:  2021-09-27       Impact factor: 14.710

3.  Delabeling Delayed Drug Hypersensitivity: How Far Can You Safely Go?

Authors:  Rannakoe J Lehloenya; Jonny G Peter; Ana Copascu; Jason A Trubiano; Elizabeth J Phillips
Journal:  J Allergy Clin Immunol Pract       Date:  2020-10

4.  Mendelian randomization analysis of celiac GWAS reveals a blood expression signature with diagnostic potential in absence of gluten consumption.

Authors:  Nora Fernandez-Jimenez; Jose Ramon Bilbao
Journal:  Hum Mol Genet       Date:  2019-09-15       Impact factor: 6.150

Review 5.  Clinical value of in vitro tests for the management of severe drug hypersensitivity reactions.

Authors:  Yuttana Srinoulprasert; Ticha Rerkpattanapipat; Mongkhon Sompornrattanaphan; Chamard Wongsa; Duangjit Kanistanon
Journal:  Asia Pac Allergy       Date:  2020-10-29

6.  Risk of True Allergy to Local Anesthetics: 10-Year Experience from an Anesthesia Allergy Clinic in China.

Authors:  Jun Zuo; Ruisong Gong; Xiaowen Liu; Jing Zhao
Journal:  Ther Clin Risk Manag       Date:  2020-12-29       Impact factor: 2.423

Review 7.  Unlocking the Non-IgE-Mediated Pseudo-Allergic Reaction Puzzle with Mas-Related G-Protein Coupled Receptor Member X2 (MRGPRX2).

Authors:  Mukesh Kumar; Karthi Duraisamy; Billy-Kwok-Chong Chow
Journal:  Cells       Date:  2021-04-27       Impact factor: 6.600

8.  Multiepitope Dendrimeric Antigen-Silica Particle Composites as Nano-Based Platforms for Specific Recognition of IgEs.

Authors:  Violeta Gil-Ocaña; Isabel M Jimenez; Cristobalina Mayorga; Inmaculada Doña; Jose Antonio Céspedes; Maria I Montañez; Yolanda Vida; Maria J Torres; Ezequiel Perez-Inestrosa
Journal:  Front Immunol       Date:  2021-12-03       Impact factor: 7.561

9.  75% negative skin test results in patients with suspected hypersensitivity to beta-lactam antibiotics: Influencing factors and interpretation of test results.

Authors:  Lukas Joerg; Susann Hasler; Anna Gschwend; Cordula Meincke; Thierry M Nordmann; Martin Glatz; Michelle Heilig; Benno Schnyder; Arthur Helbling; Peter Schmid-Grendelmeier
Journal:  World Allergy Organ J       Date:  2021-11-05       Impact factor: 4.084

10.  Bosutinib-Induced Stevens-Johnson Syndrome and Evidence of Tolerance to a Structurally Dissimilar Tyrosine Kinase Inhibitor.

Authors:  Karol Avila-Castano; Dan Morgenstern-Kaplan; Ismael Carrillo-Martin; Alexei Gonzalez-Estrada
Journal:  Cureus       Date:  2022-03-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.